NET PROFIT (x1000 EUR)
PCI Biotech Holding ASA
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
14
|
34
|
316 |
| Earnings before taxes |
-1,807
|
-5,234
|
-8,863 |
| Total assets |
3,919
|
6,031
|
13,634 |
| Current assets |
3,892
|
5,962
|
12,866 |
| Current liabilities |
443
|
547
|
2,097 |
| Equity capital |
3,473
|
5,453
|
11,410 |
| - share capital |
100
|
10,638
|
11,228 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
88.6%
|
90.4%
|
83.7% |
| Turnover per employee | |||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-45.8%
|
-86.2%
|
-62.7% |
| Current ratio |
878.6%
|
1089.9%
|
613.5% |
| Return on equity (ROE) |
-52.0%
|
-96.0%
|
-77.7% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.